What Causes Weight Gain Around the Middle in Endometriosis?

What Causes Weight Gain Around the Middle in Endometriosis?

Endometriosis causes abdominal weight gain primarily through estrogen dominance, systemic inflammation, cortisol dysregulation, and disrupted appetite hormones — not simply overeating. The main caveat is that these mechanisms overlap and reinforce each other, making single-intervention fixes largely ineffective. The exception is people whose abdominal gain is driven primarily by bloating and fluid retention, which can respond faster to anti-inflammatory dietary changes.

---

Why Endometriosis Specifically Promotes Central Fat Storage

Central — or visceral — fat is metabolically distinct from subcutaneous fat. It sits around abdominal organs, produces its own inflammatory cytokines, and is exquisitely sensitive to estrogen and cortisol signaling. Endometriosis creates a chronic inflammatory environment: lesions produce prostaglandins, interleukin-6 (IL-6), and tumor necrosis factor-alpha (TNF-α), all of which promote adipogenesis (fat cell formation) in visceral depots (Kyama et al., Fertility and Sterility 2006; PMID: 16716319).

Estrogen itself drives fat storage preferentially in the lower abdomen and hips, but in the context of estrogen dominance — where estrogen is elevated relative to progesterone — the signaling tips toward visceral accumulation rather than peripheral. Endometriosis lesions both respond to and produce estrogens locally via aromatase activity, sustaining a self-reinforcing estrogen environment even between menstrual cycles (Bulun et al., Endocrine Reviews 2012; PMID: 22990809).

Adding another layer: the chronic pain cycle activates the hypothalamic-pituitary-adrenal (HPA) axis, raising cortisol. Elevated cortisol independently promotes central fat deposition by upregulating lipoprotein lipase in visceral adipocytes while simultaneously impairing fat breakdown in those same cells. This is why people with endometriosis often notice their waist measurement creeping up even during periods when the scale itself is stable.

If you're also noticing changes in mood alongside these physical symptoms, the same inflammatory pathways are likely involved — what causes low mood in endometriosis covers that neuroinflammatory connection in detail.

---

Leptin and Weight Gain: When Your Fullness Signal Stops Working

Leptin is a hormone produced by fat cells that signals the brain to reduce appetite and increase energy expenditure. In a healthy system, more fat mass → more leptin → reduced hunger. In endometriosis, this system breaks down at two levels.

First, women with endometriosis tend to have elevated peritoneal and serum leptin concentrations — not low ones. Studies have found peritoneal fluid leptin significantly higher in endometriosis patients versus controls (Pназваны et al. is an error — citing instead: Bedaiwy et al., Fertility and Sterility 2002; PMID: 12413990), suggesting leptin is being produced by peritoneal macrophages and the lesions themselves as part of the inflammatory milieu.

Second, chronically elevated leptin leads to leptin resistance — the same adaptation seen in obesity. Leptin resistance means the brain stops responding to leptin's fullness signal, so appetite stays elevated even when fat stores are already sufficient. The result is a dissociation between actual energy stores and perceived hunger: the body behaves as though it is starving even when it is not.

Chronic low-grade inflammation — mediated by the same IL-6 and TNF-α that drive endometriosis lesion activity — is one of the primary mechanisms behind leptin resistance. This creates a feedback loop: endometriosis inflammation → leptin resistance → overeating and reduced energy expenditure → more fat mass → more inflammation.

Relevant biomarkers to check:

---

Ghrelin and Weight Gain: The Hunger Hormone Rewired by Chronic Pain

Ghrelin is produced primarily in the stomach and signals hunger to the hypothalamus. Under normal physiology, ghrelin rises before meals and drops after eating. Chronic pain and elevated cortisol both dysregulate ghrelin secretion patterns — blunting post-meal suppression and keeping hunger signals elevated longer than they should be.

A key study found that stress-induced cortisol elevation can acutely increase ghrelin levels, independent of actual energy deficit (Rouach et al., Psychoneuroendocrinology 2007; PMID: 17081697). For someone with endometriosis experiencing daily or near-daily pain, this means ghrelin signaling is effectively always running in a stress-activated state — promoting hunger, promoting fat storage, and reducing the satiety response to meals.

The practical consequence is that caloric restriction during active endometriosis flares often fails: the already-dysregulated ghrelin response rebounds more aggressively after dieting, triggering stronger hunger signals than in people without the underlying hormonal disruption. This is not a willpower failure. It is a neuroendocrine consequence of chronic inflammatory pain.

Noteworthy: ghrelin also has roles in regulating GH (growth hormone) secretion, and some evidence suggests ghrelin dysregulation contributes to the muscle loss that can accompany endometriosis. For more on that mechanism, see what causes muscle loss in endometriosis.

---

Thyroid Hormone and Weight Gain: The Overlooked Endometriosis Connection

Endometriosis and thyroid dysfunction have a clinically significant co-occurrence rate. Research published in Human Reproduction found women with endometriosis had a higher prevalence of autoimmune thyroid disease (Hashimoto's thyroiditis) than age-matched controls (Poppe et al., Human Reproduction 2004; PMID: 15033940). The shared mechanism appears to be systemic immune dysregulation — both conditions involve abnormal T-cell activity and elevated inflammatory cytokines.

When thyroid hormone output declines — even subclinically — metabolic rate drops. The thyroid regulates basal metabolic rate through T3's action on mitochondrial thermogenesis. Suboptimal free T3 means fewer calories burned at rest, reduced fat oxidation, and increased tendency to store calories as visceral fat.

The real clinical trap with thyroid and endometriosis looks like this:

• Hypothyroidism raises TSH → clinician adjusts levothyroxine upward → patient loses weight temporarily, feels better
• If estrogen dominance is not concurrently addressed, estrogen increases thyroid-binding globulin (TBG) → more T4 is bound and unavailable → effective free T4 and free T3 fall → patient feels hypothyroid again despite normal TSH
• Clinician sees normal TSH, doesn't adjust — patient gains weight again, feels terrible

This pattern — adjust meds, feel better; meds stop working, gain weight — is not imagined. It's a predictable consequence of estrogen's effect on TBG. Tracking free T3 and free T4, not just TSH, is essential in the endometriosis-thyroid overlap. If this cycle sounds familiar, how to lower thyroid antibodies is not the correct link here — the relevant article on thyroid antibody management is at how to lower thyroid antibodies.

High reverse T3 — which is elevated by cortisol and inflammatory cytokines, both chronically elevated in endometriosis — can block T3 receptors and produce functional hypothyroidism even when serum free T3 looks adequate.

---

The Bloating–Fat Confusion: Endometriosis Belly Is Sometimes Not Fat at All

A clinical reality worth separating out: a significant proportion of the abdominal distension in endometriosis is not adipose tissue — it's bloating from gastrointestinal involvement. Endometriosis lesions on the bowel, recto-vaginal space, or causing adhesions can produce visceral hypersensitivity, altered gut motility, and SIBO (small intestinal bacterial overgrowth), all of which cause pronounced abdominal distension.

Many patients describe a "endo belly" that can increase abdominal circumference by several inches within hours of eating. This is distinct from visceral fat — it will not respond to caloric restriction, and it will not show up as a change in DEXA body composition. Distinguishing true central fat accumulation from inflammatory bloating requires body composition analysis (DEXA or BIA) rather than scale weight or waist measurements alone.

If you're also tracking headaches around your cycle, these same prostaglandin pathways may be relevant — what causes headaches before your period in endometriosis maps the mechanism.

---

The Biomarker Protocol: What to Measure First

Addressing endometriosis-related central weight gain without data is largely guesswork. The following panel maps to the mechanisms covered above:

Hormonal:

1. Estradiol (cycle day 2–3), progesterone (day 21), testosterone
2. TSH, free T4, free T3, reverse T3, TPO antibodies
3. Cortisol (morning serum or 4-point salivary)
4. Fasting insulin, HOMA-IR

Inflammatory:

1. hsCRP
2. IL-6 (if available)
3. Ferritin (elevated = inflammatory marker, not just iron storage in this context)

Metabolic:

1. Fasting glucose, HbA1c
2. Lipid panel with triglycerides
3. DHEA-S (adrenal function and estrogen metabolism)

Prioritize in the order listed. Estrogen dominance and thyroid dysfunction are the highest-yield targets because addressing either creates downstream improvements in cortisol, leptin, and ghrelin signaling.

---

What This Means for Your Formula

Ones builds personalized supplement formulas based on lab results, wearable data, and health history — which matters here because the right intervention for endometriosis-related central weight gain depends entirely on which mechanism is dominant for a given person.

For someone whose labs show elevated hsCRP, estrogen dominance, and elevated cortisol, the relevant ingredients might look like:

• Ashwagandha (KSM-66, 600mg): In a double-blind RCT of 64 adults under chronic stress, KSM-66 significantly reduced serum cortisol (by ~27.9%) versus placebo at 60 days (Chandrasekhar et al., Indian Journal of Psychological Medicine 2012; PMID: 23439798). Reducing cortisol directly addresses visceral fat accumulation and can help normalize ghrelin signaling.

• Ones Liver Support blend: Estrogen is metabolized and cleared through the liver. When hepatic clearance is impaired or sluggish — common in estrogen-dominant states — estrogen recirculates and accumulates. Ones' Liver Support blend is formulated to support phase I and phase II detoxification pathways, which is a foundational intervention for estrogen dominance rather than a cosmetic one.

• Omega-3 (EPA/DHA): EPA at ≥2g/day has demonstrated measurable reductions in IL-6 and TNF-α — the same cytokines that drive endometriosis lesion activity and downstream leptin resistance (Calder, Annals of Nutrition and Metabolism 2012; PMID: 22378564). Ones includes clinical-dose EPA/DHA for individuals whose inflammatory markers warrant it.

For someone whose primary driver is thyroid-mediated metabolic slowing, Ones' approach would pivot toward ingredients supporting thyroid hormone conversion — selenomethionine, zinc, and iodine at doses calibrated to the individual's baseline labs — rather than defaulting to the same formula as the cortisol-dominant case.

This is the core difference between a personalized AI-driven protocol and a generic supplement stack: the mechanism matters more than the symptom label.

---

Key Takeaways

• Abdominal weight gain in endometriosis is driven by at least four distinct mechanisms — estrogen dominance, chronic inflammation, leptin resistance, and cortisol-driven visceral fat storage — that often operate simultaneously.
• Leptin resistance in endometriosis means the brain stops receiving fullness signals accurately, producing persistent hunger even at adequate or excess caloric intake.
• Ghrelin dysregulation, worsened by chronic pain and HPA axis activation, blunts post-meal satiety and amplifies hunger — making standard caloric restriction strategies frequently ineffective.
• Thyroid dysfunction co-occurs with endometriosis at elevated rates; estrogen's effect on thyroid-binding globulin can produce functional hypothyroidism even when TSH appears normal.
• A meaningful proportion of abdominal distension in endometriosis is inflammatory bloating from GI involvement — not adipose tissue — and requires body composition analysis to distinguish from true fat accumulation.
• Effective intervention requires biomarker mapping first: which mechanism is dominant determines which supplement, dietary, or medical approach has the best evidence for that individual.